Oncolytic adenovirus for treatment of malignant ascites

Research output: Contribution to journal › Editorial › Scientific

Original language	English
Journal	Molecular Therapy - Oncolytics
Volume	26
Pages (from-to)	302-303
Number of pages	2
ISSN	2372-7705
DOIs	https://doi.org/10.1016/j.omto.2022.07.010
Publication status	Published - 15 Sep 2022
MoE publication type	B1 Journal article

Fields of Science

@article{8bf69ebf4057421dbeb83191c8c2a68d,

title = "Oncolytic adenovirus for treatment of malignant ascites",

keywords = "3122 Cancers, Cancer-patients",

author = "Akseli Hemminki and Camilla Heini{\"o}",

note = "Funding Information: A.H. is a shareholder in Targovax ASA and an employee and shareholder in TILT Biotherapeutics Oy.",

year = "2022",

month = sep,

day = "15",

doi = "10.1016/j.omto.2022.07.010",

language = "English",

volume = "26",

pages = "302--303",

journal = "Molecular Therapy - Oncolytics",

issn = "2372-7705",

publisher = "Cell Press",

}

TY - JOUR

T1 - Oncolytic adenovirus for treatment of malignant ascites

AU - Hemminki, Akseli

AU - Heiniö, Camilla

N1 - Funding Information: A.H. is a shareholder in Targovax ASA and an employee and shareholder in TILT Biotherapeutics Oy.

PY - 2022/9/15

Y1 - 2022/9/15

KW - 3122 Cancers

KW - Cancer-patients

U2 - 10.1016/j.omto.2022.07.010

DO - 10.1016/j.omto.2022.07.010

M3 - Editorial

AN - SCOPUS:85135882537

VL - 26

SP - 302

EP - 303

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

ER -